Literature DB >> 18725050

Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.

Arthur R H van Zanten1, Kees H Polderman, Ingeborg M van Geijlswijk, Gert Y G van der Meer, Marinus A Schouten, Armand R J Girbes.   

Abstract

PURPOSE: Optimal dosing of antibiotics is important for efficacy and avoidance of resistance. Fluoroquinolones are frequently used to treat severe infections in critically ill patients. We studied ciprofloxacin pharmacokinetics after administration of 400 mg twice a day (bid) intravenously (IV).
MATERIAL AND METHODS: Serum concentrations were measured in 32 intensive care unit patients (age, 68.7 +/- 17.4 years; Sepsis-related Organ Failure Assessment (SOFA) scores, 7.3 +/- 3.4). Blood samples were drawn at 7 time points after ciprofloxacin infusion. We evaluated whether areas under the curve (AUCs) exceeded minimal inhibitory concentration (MIC) values of 0.125, 0.25, 0.5, 1.0, and 2.0 mg/L by 125 times and peak concentrations (C(max)) 10 x MIC (C(max)/MIC >10).
RESULTS: The AUC/MIC more than 125 was achieved in 100% for MIC 0.125. For MIC values 0.25, 0.5, 1.0, and 2.0, results were 84%, 31%, 3%, and 0%, respectively (P < .01). The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01). Female sex, SOFA(pulmonary) points, and SOFA(renal) points predicted higher AUC. Cumulative SOFA scores were most predictive of high AUCs.
CONCLUSIONS: Ciprofloxacin 400 mg bid IV leads to inadequate AUC/MIC and C(max)/MIC ratios in many cases. Effective killing concentrations were only achieved in pathogens with MIC less than 0.25. As bacteria in intensive care unit patients often exceed this threshold, we recommend to use higher doses of ciprofloxacin (1200 mg daily) to ensure optimal bacterial killing and avoid antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18725050     DOI: 10.1016/j.jcrc.2007.11.011

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  34 in total

1.  Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.

Authors:  Wei Zhao; Helen Hill; Chantal Le Guellec; Tim Neal; Sarah Mahoney; Stephane Paulus; Charlotte Castellan; Behrouz Kassai; Johannes N van den Anker; Gregory L Kearns; Mark A Turner; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 2.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

3.  Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.

Authors:  Stéphanie Leroux; Mark A Turner; Chantal Barin-Le Guellec; Helen Hill; Johannes N van den Anker; Gregory L Kearns; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

Review 4.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

5.  Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance.

Authors:  Stephen Y Liang; Anand Kumar
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

6.  Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease.

Authors:  Paschalina Kontou; Kalliopi Chatzika; Georgia Pitsiou; Ioannis Stanopoulos; Paraskevi Argyropoulou-Pataka; Ioannis Kioumis
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 7.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

Review 8.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

9.  Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

10.  Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options.

Authors:  R-J Hassing; W H F Goessens; D J Mevius; W van Pelt; J W Mouton; A Verbon; P J van Genderen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-23       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.